Angiotensin Converting Enzyme 2 News and Research

RSS

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

A new study revealed that the omicron variant replicates more effectively in the human bronchus than other SARS-CoV-2 variants, yet this new variant has lower replication competence in the lungs.

2 Feb 2022

Assessing an intranasal lentiviral booster against COVID-19 variants

A new study explores the possibility of vaccination via nasal route utilizing a lentiviral vaccination vector (LV) to be administered as a booster dose against COVID-19.

2 Feb 2022

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.

2 Feb 2022

Study proposes Omicron variant may be derived from recombination of two early SARS-CoV-2 PANGO lineages

A recent study showed that the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant is a chimera of two earlier PANGO lineages of SARS-CoV-2.

2 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

In a new study, a team of researchers assessed the neutralizing activity of XAV-19, a glyco-humanized polyclonal antibody derived from hyperimmunized animal hosts, against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Illustrating the structural diversity of SARS-CoV-2 Omicron spike

In a new study, a team of researchers used cryo-electron microscopy to determine the spike (S) structures of the SARS-CoV-2 Omicron variant to understand how the mutations that alter its primary sequence impact S conformation.

1 Feb 2022

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

In a new study, researchers evaluated the neutralizing antibody titers in mice vaccinated with messenger ribonucleic acid (mRNA) encoding SARS-CoV-2 spike (S) protein.

1 Feb 2022

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

In a new study, a team of researchers discovered S-217622, a non-covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate for the treatment of COVID-19.

31 Jan 2022

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Scientists have recently detected and analyzed viral PrDs in the S protein of SARS-CoV-2, which are the novel regulators of virion assembly.

31 Jan 2022

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

A new paper in the journal Molecules describes this in molecular terms, comparing SARS-CoV-2 with an earlier highly pathogenic coronavirus, SARS-CoV.

31 Jan 2022

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

Researchers identify ACE2 as the functional receptor of the two close relatives of MERS-CoV, NeoCoV and PDF-2180-CoV, in bats.

30 Jan 2022

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Researchers describe the kinetics of SARS-CoV-2-specific serum antibodies in convalescent children over six months following infection.

30 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Researchers investigate the possible efficacy of IFN-λ in the context of SARS-CoV-2 infection in mice.

28 Jan 2022

Angiotensin Converting Enzyme 2 News and Research

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

Assessing an intranasal lentiviral booster against COVID-19 variants

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Study proposes Omicron variant may be derived from recombination of two early SARS-CoV-2 PANGO lineages

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

Developing post-vaccination SARS-CoV-2 standard reference sera

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

Illustrating the structural diversity of SARS-CoV-2 Omicron spike

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News